Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Evommune (EVMN) EPS (Weighted Average and Diluted) (2024 - 2026)

Evommune (EVMN) reported EPS (Weighted Average and Diluted) of -$0.64 for Q1 2026, up 93.25% year-over-year from -$0.33 in Q1 2025, and down 104.23% on a QoQ basis from $15.14 in Q4 2025.

Evommune (EVMN) has 3 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.64 in Q1 2026.

  • Quarterly EPS (Weighted Average and Diluted) rose 93.25% year-over-year to -$0.64 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.05 (changed N/A YoY) and the FY2025 annual result came in at -$11.22, up 75.23% from the prior year.
  • EPS (Weighted Average and Diluted) retreated to -$0.64 in Q1 2026 per EVMN's latest filing, from $15.14 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $15.14 in Q4 2025 and bottomed at -$14.6 in Q4 2024.
  • The 3-year median for EPS (Weighted Average and Diluted) is -$8.78 (2025), against an average of -$4.69.
  • Peak annual rise in EPS (Weighted Average and Diluted) reached 203.7% in 2025, while the deepest fall reached 22.92% in 2025.
  • Tracing EVMN's EPS (Weighted Average and Diluted) over 3 years: stood at -$14.6 in 2024, then jumped by 203.7% to $15.14 in 2025, then tumbled by 104.23% to -$0.64 in 2026.
  • Per Business Quant, the three latest EVMN EPS (Weighted Average and Diluted) figures stand at -$0.64 (Q1 2026), $15.14 (Q4 2025), and -$8.07 (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EPS (Weighted Avg. Diluted) (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - -4.43
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn 3,086.42
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - 0.00
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn 4.02
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn 6.75
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn 1.51
10 Evommune 782.16 Mn 570.69 Mn - -0.64

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -0.64
Dec 31, 2025 15.14
Sep 30, 2025 -8.07
Mar 31, 2025 -9.48
Dec 31, 2024 -14.60
Sep 30, 2024 -10.47